Genelux Co. (NASDAQ:GNLX) Receives $26.75 Consensus Target Price from Analysts

Shares of Genelux Co. (NASDAQ:GNLX) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $26.75.

Several research firms have issued reports on GNLX. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Genelux in a research note on Thursday, August 15th. Roth Capital raised shares of Genelux to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm assumed coverage on shares of Genelux in a research report on Tuesday, August 27th. They set a “buy” rating and a $10.00 target price for the company. Finally, Benchmark lowered their target price on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a research note on Friday, May 31st.

Genelux Price Performance

GNLX stock opened at $2.17 on Thursday. Genelux has a 1-year low of $1.60 and a 1-year high of $30.44. The business has a 50-day moving average price of $2.11 and a 200 day moving average price of $3.69. The company has a market capitalization of $74.54 million, a P/E ratio of -2.24 and a beta of -1.57.

Insider Buying and Selling

In related news, major shareholder Aladar Szalay sold 107,045 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $1.98, for a total value of $211,949.10. Following the completion of the transaction, the insider now owns 925,228 shares in the company, valued at approximately $1,831,951.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 215,981 shares of company stock worth $449,177 in the last three months. Corporate insiders own 9.30% of the company’s stock.

Institutional Trading of Genelux

Several institutional investors and hedge funds have recently bought and sold shares of GNLX. Woodward Diversified Capital LLC lifted its position in Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Genelux by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock valued at $6,578,000 after buying an additional 24,220 shares during the period. Armistice Capital LLC purchased a new stake in shares of Genelux in the second quarter worth about $1,755,000. Highbridge Capital Management LLC acquired a new stake in Genelux during the second quarter worth about $1,231,000. Finally, Affinity Asset Advisors LLC purchased a new position in Genelux during the second quarter valued at approximately $195,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.